STING1 and neoplasm: In addition, due to their inherent instability, the majority of CDN-based STING agonists currently under clinical development are normally administered directly into the tumour site.103 CDNs also face obstacles such as limited intracellular bioavailability and suboptimal pharmacokinetic properties.